Galapagos, MorphoSys report Phase I data for atopic dermatitis candidate

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and MorphoSys AG (Xetra:MOR; Pink:MPSYY) reported pooled data from 25 patients with moderate to severe atopic dermatitis across all three dose cohorts in a Phase I trial showing that IV MOR106 improved Eczema Area and Severity Index (EASI) score by 58% from baseline to week four and by 72% from baseline to week 12 vs. 32% and 38%, respectively, for placebo.

Patients in the double-blind, international trial received placebo or once-weekly 1, 3 or 10 mg/kg MOR106 for four weeks. Additionally, five of six patients in the 10 mg/kg MOR106 arm achieve a ≥50% improvement in EASI (EASI 50) score at week four. MOR106 was generally well tolerated with no serious adverse events or infusion-related reactions reported. Data were presented at the American Academy of Dermatology meeting in San Diego...